KemPharm Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Corporate Updates
March 30, 2022 16:05 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Today, March 30, 2022, 5:00 p.m. ET Corporate and Regulatory Highlights Announced strategic focus on developing...
KemPharm Announces Full Data Set from Higher-Dose Serdexmethylphenidate (SDX) Phase 1 Clinical Trial
March 21, 2022 07:30 ET
|
KemPharm
Data demonstrate higher doses of SDX were generally well-tolerated and produced targeted pharmacodynamic effects that may be beneficial for the treatment of idiopathic hypersomnia (IH) and other sleep...
FDA Grants Vitality Biopharma Orphan Drug Designation for VBX-100 Prodrug
August 10, 2021 09:00 ET
|
Vitality Biopharma, Inc
CLEVELAND, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (OTC: VBIO) (“Vitality” or the “Company”), an innovation-driven drug development company dedicated to unlocking the therapeutic...
KemPharm to Report Second Quarter 2021 Results
August 05, 2021 07:30 ET
|
KemPharm
Conference Call and Live Audio Webcast with Slide Presentation Scheduled for Thursday, August 12, 2021, 4:30 p.m. ET CELEBRATION, Fla., Aug. 05, 2021 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:...
Vitality Biopharma Board Update
April 27, 2020 16:52 ET
|
Vitality Biopharma, Inc
CLEVELAND, April 27, 2020 (GLOBE NEWSWIRE) -- Vitality Biopharma, Inc. (Ticker: VBIO) (“Vitality Biopharma,” “Vitality,” or the “Company”), a corporation dedicated to the development of cannabinoid...
Praxis Bioresearch Awarded $1.5 Million Fast-Track SBIR Grant for Development of Novel Prodrug Stimulant with Abuse-Deterrent Properties
August 07, 2018 08:05 ET
|
Praxis Bioresearch
MENLO PARK, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Announces Peer-Reviewed Publication of Positive Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties
March 28, 2018 08:05 ET
|
Praxis Bioresearch
MENLO PARK, Calif., March 28, 2018 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...
Praxis Bioresearch Presents Positive Preclinical Data for Novel Prodrug Stimulant with Abuse-Deterrent Properties at ACNP Annual Meeting
December 07, 2017 07:35 ET
|
Praxis Bioresearch
MENLO PARK, Calif., Dec. 07, 2017 (GLOBE NEWSWIRE) -- Praxis Bioresearch, a biopharmaceutical company focused on the discovery and development of novel therapeutics for chronic neuropsychiatric and...